RT Book, Section
A1 Spivak, Jerry L.
A2 Longo, Dan L.
SR Print(0)
ID 1128353898
T1 POLYCYTHEMIA VERA AND OTHER MYELOPROLIFERATIVE DISEASES
T2 Harrison's Hematology and Oncology, 2e
YR 2013
FD 2013
PB McGraw-Hill Education
PP New York, NY
SN 9780071814904
LK hemonc.mhmedical.com/content.aspx?aid=1128353898
RD 2024/04/19
AB The  World  Health  Organization  (WHO)  classification  of  the  chronic  myeloproliferative  diseases  (MPDs)  includes  eight  disorders,  some  of  which  are  rare  or  poorly  characterized  (Table  13-1)  but  all  of  which  share  an  origin  in  a  multipotent  hematopoietic  progenitor  cell;  overproduction  of  one  or  more  of  the  formed  elements  of  the  blood  without  significant  dysplasia;  a  predilection  to  extramedullary  hematopoiesis,  myelofibrosis;  and  transformation  at  varying  rates  to  acute  leukemia.  Within  this  broad  classification,  however,  significant  phenotypic  heterogeneity  exists.  Some  diseases  such  as  chronic  myeloid  leukemia  (CML),  chronic  neutrophilic  leukemia  (CNL),  and  chronic  eosinophilic  leukemia  (CEL)  express  primarily  a  myeloid  phenotype,  while  in  others  such  as  polycythemia  vera  (PV),  primary  myelofibrosis  (PMF),  and  essential  thrombocytosis  (ET),  erythroid  or  megakaryocytic  hyperplasia  predominates.  The  latter  three  disorders,  in  contrast  to  the  former  three,  also  appear  capable  of  transforming  into  each  other.